Impact of co-infection of streptococcus pneumoniae and pneumococcal vaccination on the clinical outcomes of coronavirus disease 19.
10.3760/cma.j.cn112150-20211119-01072
- Author:
Yun Hua BAI
1
;
Zheng ZHANG
1
;
Shu Ping LI
1
Author Information
1. Department of Biological Products, Chaoyang District Center for Disease Prevention and Control of Beijing, Beijing 100020, China.
- Publication Type:Journal Article
- MeSH:
Aged;
COVID-19;
Coinfection;
Humans;
Pneumococcal Infections/prevention & control*;
Streptococcus pneumoniae;
Vaccination
- From:
Chinese Journal of Preventive Medicine
2022;56(5):659-667
- CountryChina
- Language:Chinese
-
Abstract:
Coronavirus disease 19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 has spread all over the world. Streptococcus pneumoniae as a common pathogen of community-acquired pneumonia shares similar high-risk susceptible populations with COVID-19. Streptococcus pneumoniae co-infection is a key risk factor for severe COVID-19 and death. Pneumococcal vaccination has a beneficial impact on reducing the incidence and mortality of COVID-19. The vaccination rate of streptococcus pneumoniae is still low in China. Streptococcus pneumoniae vaccination may be one of effective strategies in the management of COVID-19 for high-risk population such as the elderly and those who have underlying chronic diseases.
